Idarucizumab for Dabigatran-Related Gastrointestinal Bleeds

Deborah M Siegal^{1

2}, Stuart J Connolly^{1

2}

Affiliations

¹ Department of Medicine, McMaster University, Hamilton, Ontario, Canada (D.M.S., S.J.C.).
² Population Health Research Institute, Hamilton, Ontario, Canada (D.M.S., S.J.C.).

Editorial

Deborah M Siegal et al. Circulation. 2019.

. 2019 Feb 5;139(6):757-759.

doi: 10.1161/CIRCULATIONAHA.118.038460.

Deborah M Siegal^{1

2}, Stuart J Connolly^{1

2}

¹ Department of Medicine, McMaster University, Hamilton, Ontario, Canada (D.M.S., S.J.C.).
² Population Health Research Institute, Hamilton, Ontario, Canada (D.M.S., S.J.C.).

No abstract available

Keywords: Editorials; anticoagulants; dabigatran; factor Xa; gastrointestinal hemorrhage.

Comment on

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding.
Van der Wall SJ, Lopes RD, Aisenberg J, Reilly P, van Ryn J, Glund S, Elsaesser A, Klok FA, Pollack CV Jr, Huisman MV. Van der Wall SJ, et al. Circulation. 2019 Feb 5;139(6):748-756. doi: 10.1161/CIRCULATIONAHA.118.036710. Circulation. 2019. PMID: 30586692